Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotech VC (Venture Capital) Funds in Germany in October 2024

Last updated: Oct 2024 A list of 50 VC (Venture Capital) funds that invest in Biotech startups based in Germany. We rank investors based on the number of investments they made in Biotech companies from Germany. We update this investor list every month.

Top 50 Biotech VC (Venture Capital) Funds in Germany in October 2024

Investor	Biotech Germany investments
HTGF \| High-Tech Gruenderfonds	37
Boehringer Ingelheim Venture Fund	16
MIG Capital	16
KfW	16
NRW.BANK	15
Bayern Kapital	12
Wellington Partners	9
TGFS - Technologiegründerfonds Sachsen	8
IFB Innovationsstarter	7
BioMedPartners	6
coparion	6
eCAPITAL ENTREPRENEURIAL PARTNERS	6
EMBL Ventures	5
Creathor Ventures	5
BayBG Venture Capital	5
Techno Venture Management	5
bm-t beteiligungsmanagement thuringen	5
Forbion Capital Partners	5
bmp Ventures	5
BlueYard Capital	4
Seed Fonds Aachen	4
IBB Ventures	4
Amino Collective	4
Brandenburg Kapital	4
S-Venture Capital Dortmund	4
EQT Life Sciences	4
TVM Capital	4
EIC Fund	4
Andera Partners	4
b.value AG	4
Grazia Equity	4
CPT Capital	4
EQT Ventures	4
German Federal Ministry of Education and Research (BMBF)	3
OCCIDENT	3
Possible Ventures	3
DvH Ventures	3
Counteract	3
UVC Partners	3
LSP BioVentures	3
Delivery Hero Ventures	3
Lima Ventures	3
M Ventures	3
Elevat3 Capital	3
Global Asset Fund	3
Seventure Partners	3
Think.Health	3
Gilde Healthcare	3
TechVision Fund	3
SFO	3

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Information Technology, Biotechnology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

Samp — Samp accelerates modernization and de-risks contracts by connecting outdated drawings with current 3D reality captures of your facilities using our AI.
become.1 — become.1 is an employee benefits platform that eliminates the complexity of tax regulations for employees.
Symphera — An all-in-one surgical system that makes minimally-invasive procedures more efficient.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

Zusammen gestalten wir die Unternehmen von morgen.

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
Germany, France, Austria

Portfolio highlights

Inbolt — InBolt has developed the world’s smallest and most efficient 3D camera tracking system. Their first product is a hardware module / device that an operator can plug onto all manual tools such as a drill, a screwdriver or a torque wrench. Once on the tool, it guides the operator, validates the completion of a task in real time and registers allthe completion parameters.
SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
Innatera — Innatera is a Dutch nanotech company and an offspring of the Delft University of Technology in the Netherlands.

KfW gives impetus to economic, social and ecological development worldwide. As a promotional bank under the ownership of the Federal Republic and the LÃ¤nder (federal states), it offers support to encourage sustainable improvement in economic, social, ecological living and business conditions, among others in the areas of small and medium-sizedenterprise, entrepreneurialship, environmental protection, housing, infrastructure, education finance, project and export finance, and development cooperation.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Series A, Series B
Germany, India, Kenya

Portfolio highlights

Uniper — Uniper is an international energy company with about 11,000 employees. They combine a balanced portfolio of technologically advanced large-scale assets with outstanding technical and commercial expertise. Uniper is a German energy company based in Dusseldorf, North Rhine-Westphalia. It was formed by the separation of E.ON's fossil fuel assetsinto a separate company that began operating on 1 January 2016.
Vectoflow — Vectoflow is an innovative company developing fluid-dynamic metrology devices for fluid flow and dynamics measurement. It offers standardized and customized flow measurement technology that measures the static and total pressure, velocity, and angle of attack of a flow. These products are used in motorsport, aviation, turbine machine development,and research sectors.
Electrochaea — Electrochaea is commercializing a disruptive, scalable technology to convert electric power into methane, the principal component of natural gas. Using CO2 as a feedstock gas, power can be efficiently converted to renewable natural gas for power storage, for transportation fuels, or for transmission via a natural gas network. The company licensedtechnology from the University of Chicago and is led by the Nidus Partners, a St. Louis investment group specializing in renewable energy. Mich Hein, a Nidus Managing Partner, serves as CEO.Electrochaea has developed a commercially viable and disruptive solution for utility-scale energy storage, grid balancing, and carbon reuse. Their proprietary process converts low-cost and stranded electricity and carbon dioxide into pipeline-grade renewable gas for direct injection into the existing natural gas grid, a conversion process known as “power-to-gas”.

NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.

Investment focus

Biotechnology, Software, Information Technology
Seed, Series A, Series B
Germany, United States, United Kingdom

Portfolio highlights

widu — widu enables real estate and accommodation companies to source visuals (photography, video, drone) at scale through its serviced marketplace
Black Semiconductor — Black Semiconductor manufacture microchips with integrated electronic-photonic circuits using graphene technology.
Prothea Technologies — Prothea Technologies is a private medical technology business to provide lung cancer biopsy and therapy in a single hospital visit.

Bayern Kapital (founded at the end of 1995) is a wholly owned subsidiary of the LfA Foerderbank Bayern (Bavaria‘s development bank). Bayern Kapital’s objective is to finance research and development as well as the market launch of new products, product diversifications, and expansion of the market share.The requesting company has to be located inBavaria. Industries are e. g. IT/software, life sciences, new materials, micro-systems and environmental technologies.Bayern Kapital and its funds have invested in more than 250 companies and currently manages funds to the value of EUR 340 m. The five investing funds currently managed by Bayern Kapital are Seedfonds Bayern, Clusterfonds Start-Up!, Innovationsfonds, Innovationsfonds EFRE and Wachstumsfonds Bayern.

Investment focus

Software, Health Care, Information Technology
Seed, Series A, Funding Round
Germany, United States, Finland

Portfolio highlights

Symphera — An all-in-one surgical system that makes minimally-invasive procedures more efficient.
SPiNE — SPiNE is a startup that provides safe, clean, and inexpensive energy to all end users. It is focused on smart meter rollout and, as a result, digitalization in metering and control of charging infrastructure, heat pumps, and battery storage.
Marvel Fusion — Our mission is to enable humankind to access clean, safe & reliable energy by building a laser-driven fusion power plant.

Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Funding Round
Germany, United States, United Kingdom

Portfolio highlights

SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
UroMems — The device is developing an active implantable medical device based on the cutting edge technologyl in the field of embedded systems and micro-technologies for the development of its products.
Onward — Working to restore movement, independence, and health in people with spinal cord injury.

TGFS - Technologiegruenderfonds Sachsen is an early stage VC fund targeting high tech startups with strong growth potential. The fund invests into ventures located in Saxony/Germany, Europe's leading semiconductor cluster. The team has invested into more than 120 companies so far, including more than 40 investments from the currentfund.

Investment focus

Software, Information Technology, Manufacturing
Seed, Funding Round, Series A
Germany, United States

Portfolio highlights

In.hub — in.hub is a specialist in condition monitoring of machines, processes, and products, offering digitalisation options in the industrial environment. It connects legacy and modern systems, creates condition monitoring systems, and generates information for optimal planning and control.
Packwise — Packwise is bringing Intermediate Bulk Containers (IBCs) to the Internet of Things. Their Packwise Smart Cap makes a container intelligent and allows for improved and automated packaging management and logistics. Millions of IBCs are being used by chemical, pharmaceutical and food companies every day. Their Packwise Smart Cap is narrow-band LPWANconnected and provides users with real-time information on the state and location of containers.Packwise develops ready-to-use web applications and can be integrated with existing in-house IT or software through web service API.Packwise GmbH is a German company based in the Silicon Saxony. Packwise is Europe’s pioneer in digital industrial packaging management (IBCs and drums).
watttron — Watttron invents a revolutionary heating system that can heat up surfaces heterogeneously.Watttron develops an innovative heating technology that can be used in various industrial processes. It is superior to current heating systems in many ways and offers a number of advantages. On the following pages, you will find information about possibleapplications and opportunities.The company is located in the Technologie- und Gründerzentrum Freital – a technology and start-up center on the outskirts of Dresden, the state capital of Saxony.

The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.

Investment focus

Software, SaaS, Artificial Intelligence
Seed, Funding Round, Grant
Germany, United States

Portfolio highlights

3D Spark — Profitability and Sustainability Aligned using 3D Spark's Platform - Empowering Manufacturing with Insights and Efficiency!
Stargazr — Stargazr is a AI-powered software that enables you to understand your financial data
Neuralfinity — Neuralfinity provides computer AI services. They generalise machine learning models by utilising an ML API as a service.

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Switzerland, Germany, France

Portfolio highlights

Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.

Investment focus

Software, SaaS, FinTech
Series A, Seed, Series B
Germany, Switzerland, United States

Portfolio highlights

Finoa — Finoa is the leading European crypto-asset management platform, empowering businesses and institutions to engage with crypto safely and intuitively.
Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

eCAPITAL is a venture capital investor that provides early to growth stage funding to technology and deep tech companies.

Investment focus

Information Technology, Software, Manufacturing
Series A, Funding Round, Series B
Germany, United States, Italy

Portfolio highlights

Exein — Exein provides the most advanced IoT security solution to protect your devices and containers. Protect your IoT devices in real time and at scale.
BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
Dryad Networks — Overview of Dryad, providing ultra-early fire detection as well as forest growth and health monitoring.

EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
Germany, Austria, Ireland

Portfolio highlights

Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

We have been investing at the frontier of technology and science for over 30 years. We know what it takes to succeed.

Investment focus

Software, Health Care, Biotechnology
Series A, Funding Round, Series B
Germany, Switzerland, United States

Portfolio highlights

Ledgy — Digitize your cap table, automate equity plans and simplify compliance. Find out how leading companies use Ledgy to empower their employees and engage investors.
HeyJobs — Intelligent recruiting | more hires with performance marketing | only qualified candidates | fast recruiting success | over 1,500 companies use HeyJobs to find employees
Humanoo — HUMANOO | MAKING PEOPLE HEALTHIER! HUMANOO is the digital health platform for employees and insurance clients. We enable our users to improve their physical and mental health. Simple, effective, proven - all in one app. With customized programs and innovative eHealth solutions, we guide our users in the areas of fitness, physio, yoga, mindfulnessand nutrition to their self-imposed goals. For the first time, companies and insurance companies can use comprehensive decentralized analysis to understand the health of their employees or insurance clients and make it a measurable success. Our team currently consists of 65 employees from 15 nations with different talents. In our office in Berlin-Kreuzberg, software developers, designers, marketing and sales specialists work together with sports and nutrition scientists as well as yoga teachers and physiotherapists. What we share is the goal to motivate people to stay healthy.

Innovative post-revenue startups with first customers trust us as highly reliable investors. We have been an active player in the venture capital market for over 25 years. Due to our evergreen approach, we offer institutional venture capital without the limitations of the usual fund structure. Predominantly we invest straight equity. Additionally,we can offer venture debt to mature startups close to break-even in order to avoid further dilution for founders. Being a private investment company we act as both lead investor or co-investor. We can also fulfill the private lead investor role for public investors like Bayern Kapital. Together we are increasing YOUR company's value.

Investment focus

Software, Information Technology, Health Care
Funding Round, Series A, Series B
Germany, Italy, United States

Portfolio highlights

memtime — memtime shows you everything you worked on during the day. Each program is recorded so that you can quickly remember. Add-on available for any software. | memtime
StoryBox — StoryBox provides a Software as a Service solution for businesses to create, share and structure video content to make it searchable. With the system, companies can create and organize smartphone-based videos for any application scenario. Using the app, videos can be created and shared by every employee using templates. The app suggests picturesettings and scene lengths automatically and offers an automated creation which includes corporate design. The content can be stored in the DSGVO-compliant StoryBox cloud and can be accessed, filtered and analyzed from anywhere. Customers include Iveco, Erste Group, Evonik, Alten, and KTM.
Kloster Kitchen — Kloster Kitchen is a monastery kitchen as the root of unique taste.

Techno Venture Management is a venture capital and private equity firm focused on healthcare industry.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, Germany, United Kingdom

Portfolio highlights

Streaming21 — Checkout the full domain details of Streaming21.com. Click Buy Now to instantly start the transaction or Make an offer to the seller!
Revolt Technology — News & Informations
Helomics — Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

bm|t supports innovative and growth-oriented companies in Thuringia with equity investments and venture capital.

Investment focus

Software, Information Technology, Health Care
Seed, Funding Round, Series A
Germany, United States

Portfolio highlights

tediro — tediro develops a mobile robotics platform for multiple applications in healthcare primarily therapy and diagnostics
Enginsight — Enginsight GmbH was founded in August 2017. With a highly motivated team, they are working together on the vision of providing companies with a solution that will enable them to safely and confidently navigate the digital future. Enginsight helps leading companies autonomously monitor and secure their entire IT landscape. Certified and highlytrained employees form the heart of Enginsight, together with partner companies around the globe. They analyze and monitor complete IT landscapes – recognize the connections and dependencies between websites and servers up to IoT-devices. The innovative software platform acts autonomously and points out the critical paths, risks and threats.
Coachwhisperer — Coachwhisperer: The live communication system for sports. We take training to the next level and help coaches and athletes reach their true potential.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Navigator Medicines — Leading the advancement of biologics for targeted immune regulation & restoration.
Bicycle Therapeutics — Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

bmp Ventures is an innovative Venture Capital Company from Berlin. Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.

Investment focus

Information Technology, Software, Manufacturing
Seed, Funding Round, Series A
Germany, United States, Austria

Portfolio highlights

Neotiv — Enabling cognitive health
RAYDIAX — We are Raydiax.Interventional only.Our goal is to reinvent computer tomography that is focussed on treatment.
XenoPatch GmbH — First-ever portable device for pain management, seamlessly combines heat, cold and vibration treatment with an intuitive smartphone app.

BlueYard backs founders building the interconnected elements that can become the fabric of our future.

Investment focus

Software, Biotechnology, Internet
Seed, Series A, Funding Round
United States, Germany, United Kingdom

Portfolio highlights

CPTx — At CPTx, we develop new treatment paradigms across outsized medical challenges, with an initial focus on infectious diseases. The flexibility and precision of CPTx's platform supports multivalent drug development, which is crucial for addressing complex disease states involving multiple binding sites, such as viruses, cancer, and autoimmune diseases.
Insempra — Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance.
ExpressionEdits — Redefining the status quo of protein expression

Seed Fonds has a strong competence network with national and international investors, business angels & expertes from the industry. They are specialized in the development of comprehensive financing models offering stability and development opportunities on the long term.

Investment focus

Biotechnology, Medical, Health Care
Funding Round, Seed, Series A
Germany

Portfolio highlights

miacosa — miacosa.de is operated by the Endorsed Goods GmbH. miacosa.de is a social shopping concept from Germany based in Cologne. Social Shopping the miacosa way means that members select their personal shopping team of experts and celebrities that present products they love on miacosa.de Miacosa is for members only. The free service starts with productsfrom the fields of Health Style, Home & Living, Kitchen and fashion accessories.
Hemovent — Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop aninnovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.
aquila biolabs — aquila biolabs is a German technology company focusing on the development of innovative laboratory devices for the analysis of shake-flask fermentations in biotechnological, chemical and pharmaceutical research and development.

IBB Ventures is a venture capital and mezzanine arm of Investitionsbank Berlin specializing in seed/startup, early venture, and mid venture investments. The firm invests in technology-oriented companies and companies from the creative industries. It typically invests in information and communication sector with a focus on hardware andsoftware, network technology, new media, and internet and mobile technologies; life science sector with a focus on biotechnology and media technology; and industrial technologies sector with a focus on software, PPS, supply chain management, micro and nanotechnology, environmental and power technology, automation, manufacturing technology, transport technology and logistics, and new materials. The firm also invests in movies, broadcast, television, publisher, music, entertainment, advertising, fashion, design, architecture, multimedia, games, software, and art and culture. It invests in companies based in Berlin. It typically invests between €0.25 million ($0.32 million) and €3 million ($3.83 million) per transaction. The firm prefers to take a board seat in its portfolio companies. IBB Ventures was founded in 1997 and is based in Berlin, Germany.

Investment focus

Software, Health Care, Internet
Seed, Funding Round, Series A
Germany, United States, United Kingdom

Portfolio highlights

eco.mio — eco.mio enables companies to reach their climate targets while realizing significant savings: Incentivize employees to travel consciously with eco mio's end-to-end integrated software solution.
Ucaneo — We Leveraging the magic of the human body to remove CO2 from the air.
Northbound — We are building the dynamic decision engine that translates real-time data into operational excellence & stakeholder transparency. All at the intersection of warehouse and transport logistics.

Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Pre-Seed
United States, Germany, United Kingdom

Portfolio highlights

Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
ExpressionEdits — Redefining the status quo of protein expression
Tandem Health — Focus on providing care, while Tandem helps you easily write medical notes directly after the patient consultation.

With a track record of over 20 years in venture capital and experience from more than 200 investments in numerous companies BFB Brandenburg Kapital GmbH (BFB) is the most active equity investor in Brandenburg. BFB invests in fast-growing technology-orientated companies throughout the whole life-cycle. Target sectors are ICT/Digital Economy,Life Science, MedTech, Proptech, Industrial Applications. BFB invests in companies based in or with facilities in Brandenburg. The current VC fund is financed by the European Regional Development Fund (ERDF) an Investitionsbank des Landes Brandenburg (ILB).

Investment focus

Software, Information Technology, Health Care
Seed, Series A, Funding Round
Germany, United Kingdom

Portfolio highlights

Mateo — Mateo is the omni-channel customer experience powerhouse that empowers local brands and businesses to drive growth through a digital customer lifecycle management. From acquiring new leads, converting them into customers and extending those relationships - all in one platform.
family.cards — Family.cards provides elders with barrier-free access to digital solutions and all the tools they need to manage their circumstances.
Captain T Cell — Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients. The company identifies novel high-efficiency TCRs for the development of T cell immunotherapies. It focuses on CMC- and preclinical development for their lead candidates.

S-Venture Capital Dortmund aims to fund technology companies and is a German regional investment group.

Investment focus

Biotechnology, Guides, Genetics
Series B, Funding Round, Series A
Germany

Portfolio highlights

Innolume — Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power.
Protagen — Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.
Scienion — SCIENION AG is a life science company well positioned in the markets of ultra-low volume liquid handling systems and microarray technologies. They provide their customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomicsand proteomics fields â€“ from early research to manufacturing.

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.

TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Funding Round, Series C
United States, Germany, United Kingdom

Portfolio highlights

Definiens — Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
Lamab Biologics — Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.
Rapid Micro Biosystems — Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

start-ups, SMEs, technology, co-investment

Investment focus

Biotechnology, Health Care, Information Technology
Pre-Seed, Seed, Funding Round
Germany, The Netherlands, Austria

Portfolio highlights

Filuta AI — Operationalized Composite Artificial Intelligence
Resistell AG — Resistell is a antibiotic resistance test.
iThera Medical — Explore optoacoustic imaging technology for non-invasive in vivo visualization and quantification of disease-related tissue biomarkers.

Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.

Investment focus

Biotechnology, Health Care, Medical
Series B, Private Equity, Funding Round
France, United States, Germany

Portfolio highlights

SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
Skysun — Skysun is a financial institution that provides financial solutions and services to the solar energy sector.
Kestra Medical Technologies, Inc. — Kestra Medical Technologies is a wearable medical device and digital healthcare company that protects patients with diagnostic and therapeutic technologies that are intuitive, and mobile. They provide intuitive medical technologies to protect and support at-risk patients.

b.value AG are into Biotechnology investments.

Investment focus

Biotechnology, Military, Textiles
Seed, Pre-Seed, Funding Round
Germany

Portfolio highlights

Revoltech — Developer of textile technology intended to transform the way material is made. Revoltech‘s first product is LOVR: the world's first plastic-free and 100% plant-based leather alternative made of agricultural residues.
PL BioScience — Animal-free cell culture supplements derived from human platelets. Supporting cell expansion and maintenance from research to therapy.
Cultimate Foods — Cultimate Foods is a cellular agriculture company. It develops cultivated fat for hybrid alt-meat products. It's cultivated fat replicates the structure of animal fat tissue and it uses a "unique technological approach to 3D cultivation that creates the structure of their ingredient and reduces production costs."

Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.

Investment focus

Internet, E-Commerce, Biotechnology
Series A, Seed, Series B
Germany, United States, Switzerland

Portfolio highlights

ZAGENO — ZAGENO is a multi-vendor, online marketplace of life science products which, by simplifying the procurement process, saves more time for science.
XO Life — XO Life is to build the largest real-world evidence platform for patient insights for all medications and therapies. Together with one of Europe's leading research institutes for patient-centered research, the PROMIS Institute Germany of the Charité, and various pharmaceutical manufacturers, patient experiences are to be recorded in astandardized and systematic manner across a wide range of diseases. Patients are to be enabled to record their therapy course and outcome independently as well as scientifically validated so that these patient insights from real treatment practice can be used in the life science industry and by medical professions.
Formo — We're Formo, the future of dairy. Using micro fermentation, we create animal-free cheeses that humans love.

Investing in the Future of Protein.We invest in visionary founders creating the future of food and materials.

Investment focus

Food and Beverage, Food Processing, Biotechnology
Series A, Seed, Series B
United States, Israel, United Kingdom

Portfolio highlights

ENOUGH — ENOUGH makes protein sustainable by producing ABUNDA mycoprotein, made by fermenting fungi with the natural sugars from grains. It is a whole protein with all 9 essential amino acids & rich in fibre. It is a B2B ingredient, neutral in taste and fibrous in texture, like meat. The most sustainable
PoLoPo — PoLoPo is a biotech company that produces proteins on a large scale and according to specifications. PoLoPo develops a "superAA" plant by employing directed metabolic engineering techniques and fully utilizing plants' capacity as various metabolite and green protein factories. A significant amount of free amino acids can be producedby the superAA. The increased production of amino acids is then translated into an increase in the scale at which proteins are produced in plant organs.
Wanda Fish Technologies — Wanda Fish is an innovative FoodTech company with a platform that produces a wide variety of delicious fish fillets using sustainable cell-cultivation practices.

EQT Ventures is a European VC fund with just over €2.3 billion in total capital raised. EQT Ventures I launched in May 2016, with commitments totaling €566 million and a simple mission - to be the kind of VC the team would have liked to have had on their own startup journeys. Recognizing that building and growing a company takes more than justcapital, the EQT Ventures team provides founders with support and advice throughout different stages of growth. EQT Ventures doesn't focus on particular markets or industries, but on bold and ambitious founders who have the grit and determination to build global success stories. EQT Ventures II launched in November 2019, with commitments totaling €660 million. EQT Ventures III launched in 2022, with commitments totaling €1.1 billion, making it the biggest European Venture Capital fund committed to early-stage tech startups. The EQT Ventures team is based across six offices in London, Stockholm, Berlin, Paris, Amsterdam, Paris, and San Francisco, taking a locals-with-locals approach and supporting founders on the ground. Motherbrain, EQT Ventures' in-house-developed artificial intelligence (AI) platform, ensures the team has a data-driven approach and has driven more than $100 million in portfolio company investments.

Investment focus

Software, Information Technology, Artificial Intelligence
Series A, Series B, Seed
Sweden, Germany, United States

Portfolio highlights

VidLab7 — VidLab7 is a platform focused on synthetic media, specifically tailored for revenue teams. The company offers customized video experiences powered by generative AI.
Syntetica — Syntetica is a nylon recycling startup that addresses pollution in the fashion industry by transforming discarded nylon products into high-quality, reusable materials. Their innovative processes help reduce waste, conserve resources, and promote sustainability within the fashion sector.
Vsim Technology — Experience the power of next-generation physics simulations with Vsim. Our cutting-edge technology provides realistic and accurate simulations for various industries.

German Federal Ministry of Education and Research (BMBF)

Investment focus

Biotechnology, Medical, Health Care
Grant, Seed, Series B
Germany, United States, Denmark

Portfolio highlights

eClear — eClear is a Pan-European payment facilitator providing Customs & VAT Clearing as embedded checkout-solution for marketplaces & platforms.
Evotec — Evotec is a global biotechnology company committed to advancing drug discovery & development together with our partners for medicines that matter.
NVision Imaging Technologies — NVision Imaging Technologies is leveraging advances in quantum physics to enable the first routine, convenient and affordable use of Magnetic Resonance Imaging (MRI) for assessing early patient response to cancer treatment at the metabolic level.

Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments. Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.

Investment focus

Health Care, Medical Device, Biotechnology
Series A, Series B, Series C
Germany, Switzerland, Slovenia

Portfolio highlights

ReCatalyst — REvolutionizing the way we make fuel cell CATALYSTs
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Lunaphore — Lunaphore Technologies is a spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research

Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.

Investment focus

Software, Information Technology, Biotechnology
Seed, Pre-Seed, Series A
Germany, Australia, United States

Portfolio highlights

Insempra — Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance.
Sumday — Non - financial accounting software. Start carbon accounting, properly, with the support of your existing advisors
InSpacePropulsion Technologies — ISPTech is a Spin-Off of the Institute of Space Propulsion at the German Aerospace Center (DLR). It offers non-toxic, green propulsion solutions

Investing early in Europe's most passionate founders.

Investment focus

Health Care, Financial Services, Software
Seed, Series A, Funding Round
Germany, Austria, United Kingdom

Portfolio highlights

LiveEO — LiveEO is the leading solution provider for AI-powered satellite-based monitoring of large infrastructure networks. Trusted worldwide.
OneTwenty — OneTwenty is an early-stage health tech start-up that develops multiple Machine Learning based solutions for people with diabetes as well as Medtech companies for sensor optimization, biomarker prediction, glucoregulatory models, and iAGC (interoperable automated glycemic controller). Our solution demonstrates unprecedented precision in bloodglucose prediction 120 minutes in advance. OneTwenty revolutionizes the life of people with Type 1 diabetes.
HealthCaters — HealthCaters is a connected care solution for companies that allows them to empower their employees to take control of their health.

Carbon removal innovation through research, development and early stage investment

Investment focus

Natural Resources, Environmental Engineering, Building Material
Seed, Series A, Pre-Seed
United Kingdom, United States, Germany

Portfolio highlights

ecoLocked — ecoLocked is your partner to create a climate-positive built environment. We develop CO2-optimized recipes for concrete based on carbon-negative biochar admixes. Our admixes allow to store captured CO2 in buildings, reduce direct emissions from concrete production, and provide multiple functional benefits, such as improved thermal insulation.
Fugu — Cheap green carbon at scale for the dawn of the e-fuel age
Fugu Carbon — Fugu Carbon is a machinery manufacturing company that helps in carbon dioxide removal (CDR) technology from air.

UVC Partners is a Munich- and Berlin-based early-stage venture capital firm that invests in technology-based startups in the areas of enterprise software, industrial technologies, and mobility. The fund typically invests between € 0.5 - 10m initially and up to € 20m in total per company.

Investment focus

Software, Information Technology, SaaS
Seed, Series A, Series B
Germany, Switzerland, Denmark

Portfolio highlights

planqc — planqc quantum computers store information in individual atoms – nature's best qubits. Quantum information is processed by arranging these qubits in highly scalable arrays and manipulating them with precisely controlled laser pulses. planqc unique combination of quantum technologies is the fastest way to scale to thousands of qubits, aprerequisite for industry-relevant quantum advantage.
Enginsight — Enginsight GmbH was founded in August 2017. With a highly motivated team, they are working together on the vision of providing companies with a solution that will enable them to safely and confidently navigate the digital future. Enginsight helps leading companies autonomously monitor and secure their entire IT landscape. Certified and highlytrained employees form the heart of Enginsight, together with partner companies around the globe. They analyze and monitor complete IT landscapes – recognize the connections and dependencies between websites and servers up to IoT-devices. The innovative software platform acts autonomously and points out the critical paths, risks and threats.
Isar Aerospace — Isar Aerospace is a space technology company that builds rockets in an automated production. It offers launch services dedicated to deploying and resupplying satellite constellations and to ensure low-cost space access for small satellites. The company was founded in 2018 in Europe.

LSP BioVentures is a venture capital fund focused on opportunities in the life science arena. Based in Cambridge (MA) in the USA; the fundâ€™s management combines the strength of its parent company, Life Sciences Partners Venture Capital firm in Europe and a dedicated team of experts in the USA.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Germany, United Kingdom

Portfolio highlights

Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
HotSpot Therapeutics — HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts.

Delivery Hero Ventures is backed by Delivery Hero, a truly global food delivery platform - whose network, distribution and expertise can be harnessed to help our portfolio companies fulfill their global ambitions.

Investment focus

E-Commerce, Information Technology, Food Delivery
Series A, Seed, Series B
Singapore, Egypt, Brazil

Portfolio highlights

Charan — Charan is an operator of an e-commerce platform intended to sell second-hand fashion apparel.
Qashier — One Qashier solution streamlines POS & payment operations empowering businesses to thrive in the digital economy. Be More with Qashier.
OneOrder — One Order delivers exceptional produce, custom cuts of meat, high-quality seafood, and imported foods offering an array of global flavors.

Collaboration with outstanding initiators with exceptional insights, from inception through all levels of progress. Lima Ventures supports visionary founders as well as provides certain services to early startups. We seek innovative technology-driven entrepreneurs who generate and lead companies that will inspire millions.

Investment focus

Artificial Intelligence, Software, Digital Marketing
Seed, Pre-Seed, Funding Round
Turkey, United Kingdom, Estonia

Portfolio highlights

heybooster — Heybooster is a provider of analytical tools to ecommerce companies to take better digital marketing decisions.
Mars Studios — Mars Studios is an experienced team of growth hackers & marketers that can help you to increase your revenue. Rocket Your App to Success: Mars Studios
Enqura Information Technologies — Enqura Information Technologies offers advanced technologies in conjunction with human resources as reasonable solutions. Enqura develops creative solutions in the field of digital transformation. They provide innovative and end-to-end solutions to several industries, primarily finance and insurance.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
Formo — We're Formo, the future of dairy. Using micro fermentation, we create animal-free cheeses that humans love.
NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.

Elevat3 Capital is the venture capital arm of serial entrepreneur and investor Christian Angermayer and his family office Apeiron Investment Group. With a focus on German-speaking countries, we partner with companies that meet our three-level criteria, then elevate them by providing more than just capital. We use our exceptional network, spanningindustry, politics, arts, science and technology, to give our portfolio companies access to high-profile leads and advisors, enabling them to grow rapidly and achieve amazing results.

Investment focus

FinTech, Apps, Life Science
Series A, Series B, Post-IPO Equity
Germany, United Kingdom

Portfolio highlights

Formo — We're Formo, the future of dairy. Using micro fermentation, we create animal-free cheeses that humans love.
Naga — Join NAGA, the trusted trading platform offering 4000+ assets from multiple markets. With user-friendly platform, educational resources, and advanced features like Copy Trading and Social Newsfeed, NAGA is the perfect choice for both new and experienced traders. Sign up now and start trading on NAGA.
Legendairy Foods — We're Formo, the future of dairy. Using micro fermentation, we create animal-free cheeses that humans love.

Global Asset Fund is a private equity firm based in Germany that finances early and later stage venture investments. The fund enables the development of products and technologies that address a growing market of tomorrow.

Investment focus

Medical, Therapeutics, Biotechnology
Series A, Series B, Funding Round
Germany

Portfolio highlights

Siltectra — SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.
Isarna Therapeutics — Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Investment focus

Biotechnology, Health Care, Software
Series A, Series B, Funding Round
France, United States, Germany

Portfolio highlights

ID5 — ID5 provides a comprehensive suite of identification services designed to improve to improve addressability and measurement across all environments
Peptobiotics — We make agriculture more productive, humane and sustainable by promoting growth and protecting against pathogens using a new new type of antibiotic alternative that does not cause resistance. Our recombinant peptides are synthetic biology products manufactured in a patent pending precision fermentation process. We are launching a range of products across livestock and aquaculture in Asia.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,

Investment focus

Health Care, Biotechnology, Medical Device
Seed, Series A, Series B
Germany, United States, Switzerland

Portfolio highlights

Vara — Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with.
anvajo — Originally started at TU Dresden, anvajo can now look back on several years of innovative research and successful product development with uninterrupted growth. As part of the business expansion and ongoing team building, anvajo moved into its new headquarters in Dresden in January 2020. On 1300 m² practically all areas, including development,production and support functions are united under one roof.
Navignostics — Navignostics combines highly multiplex tumor imaging with advanced data analytics for personalized cancer treatments.

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

Investment focus

Biotechnology, Health Care, Medical
Series C, Series B, Series A
United States, The Netherlands, Germany

Portfolio highlights

Karius — Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a majorthreat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Draupnir Bio — Draupnir Bio is developing new innovative therapies for patients.

VF-Funds for innovative and scalable start-ups from the Rhineland Area, Germany

Investment focus

Software, Health Care, Manufacturing
Seed, Series A, Pre-Seed
Germany, Spain

Portfolio highlights

Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
PL BioScience — Animal-free cell culture supplements derived from human platelets. Supporting cell expansion and maintenance from research to therapy.
Black Semiconductor — Black Semiconductor manufacture microchips with integrated electronic-photonic circuits using graphene technology.

SFO is an entrepreneur from the start-up environment and medium-sized companies. SFO offers complementary expertise, reliable capital, and an effective network.

Investment focus

Food and Beverage, B2C, Pet
Seed, Pre-Seed, Series A
Germany

Portfolio highlights

Younikat — VEGDOG - vegan dog food is the first 100% vegetable and gluten-free complete feed for dogs, which was developed in a one-year development phase in cooperation with specialist veterinarians and specialist laboratories due to a feed allergy in our dog Nelson.
ecoLocked — ecoLocked is your partner to create a climate-positive built environment. We develop CO2-optimized recipes for concrete based on carbon-negative biochar admixes. Our admixes allow to store captured CO2 in buildings, reduce direct emissions from concrete production, and provide multiple functional benefits, such as improved thermal insulation.
ProteinDistillery — ProteinDistillery: The Future of Sustainable Protein Production. We transform industrial side-streams into functional protein ingredients.

Investors by industry

Artificial intelligence